Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

NCT05320757 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT05320757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05320757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
Lead sponsor
The University of Hong Kong
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2022
Completion date
May 31, 2025
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer